Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
BAY-390 is an inhibitor of transient receptor potential ankyrin 1 (TRPA1; IC50s = 16 and 63 nM for the human and rat receptor, respectively).1 It is selective for TRPA1 over a variety of receptors, ion channels, transporters, and enzymes at 10 µM but weakly inhibits estrogen receptor α (ERα), progesterone receptor B (PR-B), and the dopamine transporter (DAT; IC50s = 5,000, 5,000, and 1,200 nM, respectively). BAY-390 (3-10 mg/kg) reduces the number of flinches and the duration of paw licking in a rat model of nocifensive behavior induced by the TRPA1 agonist cinnamaldehyde and reduces inflammatory pain induced by complete Freund’s adjuvant (CFA) in rats. It also reverses mechanical allodynia in a rat model of neuropathic pain induced by spinal nerve ligation when administered at a dose of 90 mg/kg twice per day.
WARNING This product is not for human or veterinary use.
1. Discovery of BAY-